[Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report].
Identifieur interne : 000144 ( PubMed/Curation ); précédent : 000143; suivant : 000145[Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report].
Auteurs : J F Yu [République populaire de Chine] ; Y B Jin [République populaire de Chine] ; J. He [République populaire de Chine] ; Y. An [République populaire de Chine] ; Z G Li [République populaire de Chine]Source :
- Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences [ 1671-167X ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Dermatomyosite (), Dermatomyosite (sang), Femelle, Humains, Maladies du tissu conjonctif, Mucine-1 (sang), Pneumopathies interstitielles (sang), Pneumopathies interstitielles (étiologie), Sclérodermie systémique, Syndrome de Gougerot-Sjögren (), Syndrome de Gougerot-Sjögren (sang).
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , blood : Mucin-1.
- blood : Dermatomyositis, Lung Diseases, Interstitial, Sjogren's Syndrome.
- complications : Dermatomyositis, Sjogren's Syndrome.
- etiology : Lung Diseases, Interstitial.
- Connective Tissue Diseases, Female, Humans, Middle Aged, Scleroderma, Systemic.
Abstract
Interstitial lung diseases (ILDs) are a diverse group of pulmonary disorders characterized by various patterns of inflammation and fibrosis in the interstitium of the lung. The underlying pathogenesis of ILDs is complex and associated with multiple rheumatologic conditions, such as systemic sclerosis, rheumatoid arthritis, pollymyositis and dermatomyositis, Sjögren's syndrome, and systemic lupus erythematosus. As the disease progresses, excessive pulmonary fibrosis impairs alveolar gas exchange and damages pulmonary function. The common methods to diagnose ILDs, such as clinical manifestations, pulmonary function test, and radiological examinations are not specific for ILDs and not able to diagnose ILDs at the early stage due to their low sensitivity. So, the easy way is important to diagnose ILDs. One important biomarker for ILDs is the high-molecular-weight glycoprotein, Krebs von den Lungen-6(KL-6). KL-6 encoded by the MUC1 gene is a mucin-like glycoprotein with high molecular weight and expressed predominantly on the cell surface of type II alveolar epithelial cells, and is detectable in the serum of patients with ILDs. We here report a case of ILDs associated with dermatomyositis and secondary Sjögren's syndrome. A 60-year-old woman was admitted to our hospital with the chief complaints of debilitation, dry mouth, dyspnea and astasia. ILDs associated with dermatomyositis and secondary Sjögren's syndrome was diagnosed clinically when the following criteria were satisfied: (1) development of dyspnea within 2 months of presentation, (2) pulmonary dispersion dysfunction, (3) bilateral infiltrative shadows on chest high resolution computed tomography (HRCT). She was treated with prednisone 50 mg/d prior to admission, but the result of therapy was not good. In our hospital she was treated with intravenous methylprednisolone and cyclophosphamide and oral hydroxychloroquine sulfate. Subsequently, her serum KL-6 levels gradually decreased after treatment, pulmonary diffuse function improved, and the improvement in the clinical manifestation and HRCT findings were observed. Nevertheless, the combination treatment of glucocorticoid and cyclophosphamide had contributed to the favourable outcomes. In conclusion, detection of serum KL-6 levels in ILDs associated with connective tissue diseases may be beneficial to making a definitive diagnosis, predicting the prognosis and monitoring the disease activity, which would be of great help in clinical practice. However, a well-designed clinical study with more patients and a longer follow-up period are required to arrive at a more conclusive judgment on the role of serum KL-6 in patients with ILDs.
PubMed: 29045979
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000144
Links to Exploration step
pubmed:29045979Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report].</title>
<author><name sortKey="Yu, J F" sort="Yu, J F" uniqKey="Yu J" first="J F" last="Yu">J F Yu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China; Department of Nephrology and Rheumatology, The Third People's Hospital in Hubei Province, Wuhan 430000, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China; Department of Nephrology and Rheumatology, The Third People's Hospital in Hubei Province, Wuhan 430000</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jin, Y B" sort="Jin, Y B" uniqKey="Jin Y" first="Y B" last="Jin">Y B Jin</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="He, J" sort="He, J" uniqKey="He J" first="J" last="He">J. He</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="An, Y" sort="An, Y" uniqKey="An Y" first="Y" last="An">Y. An</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Z G" sort="Li, Z G" uniqKey="Li Z" first="Z G" last="Li">Z G Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:29045979</idno>
<idno type="pmid">29045979</idno>
<idno type="wicri:Area/PubMed/Corpus">000144</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000144</idno>
<idno type="wicri:Area/PubMed/Curation">000144</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000144</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report].</title>
<author><name sortKey="Yu, J F" sort="Yu, J F" uniqKey="Yu J" first="J F" last="Yu">J F Yu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China; Department of Nephrology and Rheumatology, The Third People's Hospital in Hubei Province, Wuhan 430000, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China; Department of Nephrology and Rheumatology, The Third People's Hospital in Hubei Province, Wuhan 430000</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jin, Y B" sort="Jin, Y B" uniqKey="Jin Y" first="Y B" last="Jin">Y B Jin</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="He, J" sort="He, J" uniqKey="He J" first="J" last="He">J. He</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="An, Y" sort="An, Y" uniqKey="An Y" first="Y" last="An">Y. An</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Li, Z G" sort="Li, Z G" uniqKey="Li Z" first="Z G" last="Li">Z G Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences</title>
<idno type="ISSN">1671-167X</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Connective Tissue Diseases</term>
<term>Dermatomyositis (blood)</term>
<term>Dermatomyositis (complications)</term>
<term>Female</term>
<term>Humans</term>
<term>Lung Diseases, Interstitial (blood)</term>
<term>Lung Diseases, Interstitial (etiology)</term>
<term>Middle Aged</term>
<term>Mucin-1 (blood)</term>
<term>Scleroderma, Systemic</term>
<term>Sjogren's Syndrome (blood)</term>
<term>Sjogren's Syndrome (complications)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Dermatomyosite ()</term>
<term>Dermatomyosite (sang)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Maladies du tissu conjonctif</term>
<term>Mucine-1 (sang)</term>
<term>Pneumopathies interstitielles (sang)</term>
<term>Pneumopathies interstitielles (étiologie)</term>
<term>Sclérodermie systémique</term>
<term>Syndrome de Gougerot-Sjögren ()</term>
<term>Syndrome de Gougerot-Sjögren (sang)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Mucin-1</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Dermatomyositis</term>
<term>Lung Diseases, Interstitial</term>
<term>Sjogren's Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dermatomyositis</term>
<term>Sjogren's Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lung Diseases, Interstitial</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Dermatomyosite</term>
<term>Mucine-1</term>
<term>Pneumopathies interstitielles</term>
<term>Syndrome de Gougerot-Sjögren</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Pneumopathies interstitielles</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Connective Tissue Diseases</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Scleroderma, Systemic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Dermatomyosite</term>
<term>Femelle</term>
<term>Humains</term>
<term>Maladies du tissu conjonctif</term>
<term>Sclérodermie systémique</term>
<term>Syndrome de Gougerot-Sjögren</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Interstitial lung diseases (ILDs) are a diverse group of pulmonary disorders characterized by various patterns of inflammation and fibrosis in the interstitium of the lung. The underlying pathogenesis of ILDs is complex and associated with multiple rheumatologic conditions, such as systemic sclerosis, rheumatoid arthritis, pollymyositis and dermatomyositis, Sjögren's syndrome, and systemic lupus erythematosus. As the disease progresses, excessive pulmonary fibrosis impairs alveolar gas exchange and damages pulmonary function. The common methods to diagnose ILDs, such as clinical manifestations, pulmonary function test, and radiological examinations are not specific for ILDs and not able to diagnose ILDs at the early stage due to their low sensitivity. So, the easy way is important to diagnose ILDs. One important biomarker for ILDs is the high-molecular-weight glycoprotein, Krebs von den Lungen-6(KL-6). KL-6 encoded by the MUC1 gene is a mucin-like glycoprotein with high molecular weight and expressed predominantly on the cell surface of type II alveolar epithelial cells, and is detectable in the serum of patients with ILDs. We here report a case of ILDs associated with dermatomyositis and secondary Sjögren's syndrome. A 60-year-old woman was admitted to our hospital with the chief complaints of debilitation, dry mouth, dyspnea and astasia. ILDs associated with dermatomyositis and secondary Sjögren's syndrome was diagnosed clinically when the following criteria were satisfied: (1) development of dyspnea within 2 months of presentation, (2) pulmonary dispersion dysfunction, (3) bilateral infiltrative shadows on chest high resolution computed tomography (HRCT). She was treated with prednisone 50 mg/d prior to admission, but the result of therapy was not good. In our hospital she was treated with intravenous methylprednisolone and cyclophosphamide and oral hydroxychloroquine sulfate. Subsequently, her serum KL-6 levels gradually decreased after treatment, pulmonary diffuse function improved, and the improvement in the clinical manifestation and HRCT findings were observed. Nevertheless, the combination treatment of glucocorticoid and cyclophosphamide had contributed to the favourable outcomes. In conclusion, detection of serum KL-6 levels in ILDs associated with connective tissue diseases may be beneficial to making a definitive diagnosis, predicting the prognosis and monitoring the disease activity, which would be of great help in clinical practice. However, a well-designed clinical study with more patients and a longer follow-up period are required to arrive at a more conclusive judgment on the role of serum KL-6 in patients with ILDs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29045979</PMID>
<DateCompleted><Year>2019</Year>
<Month>02</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>02</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1671-167X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>49</Volume>
<Issue>5</Issue>
<PubDate><Year>2017</Year>
<Month>10</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences</Title>
<ISOAbbreviation>Beijing Da Xue Xue Bao</ISOAbbreviation>
</Journal>
<ArticleTitle>[Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report].</ArticleTitle>
<Pagination><MedlinePgn>910-914</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Interstitial lung diseases (ILDs) are a diverse group of pulmonary disorders characterized by various patterns of inflammation and fibrosis in the interstitium of the lung. The underlying pathogenesis of ILDs is complex and associated with multiple rheumatologic conditions, such as systemic sclerosis, rheumatoid arthritis, pollymyositis and dermatomyositis, Sjögren's syndrome, and systemic lupus erythematosus. As the disease progresses, excessive pulmonary fibrosis impairs alveolar gas exchange and damages pulmonary function. The common methods to diagnose ILDs, such as clinical manifestations, pulmonary function test, and radiological examinations are not specific for ILDs and not able to diagnose ILDs at the early stage due to their low sensitivity. So, the easy way is important to diagnose ILDs. One important biomarker for ILDs is the high-molecular-weight glycoprotein, Krebs von den Lungen-6(KL-6). KL-6 encoded by the MUC1 gene is a mucin-like glycoprotein with high molecular weight and expressed predominantly on the cell surface of type II alveolar epithelial cells, and is detectable in the serum of patients with ILDs. We here report a case of ILDs associated with dermatomyositis and secondary Sjögren's syndrome. A 60-year-old woman was admitted to our hospital with the chief complaints of debilitation, dry mouth, dyspnea and astasia. ILDs associated with dermatomyositis and secondary Sjögren's syndrome was diagnosed clinically when the following criteria were satisfied: (1) development of dyspnea within 2 months of presentation, (2) pulmonary dispersion dysfunction, (3) bilateral infiltrative shadows on chest high resolution computed tomography (HRCT). She was treated with prednisone 50 mg/d prior to admission, but the result of therapy was not good. In our hospital she was treated with intravenous methylprednisolone and cyclophosphamide and oral hydroxychloroquine sulfate. Subsequently, her serum KL-6 levels gradually decreased after treatment, pulmonary diffuse function improved, and the improvement in the clinical manifestation and HRCT findings were observed. Nevertheless, the combination treatment of glucocorticoid and cyclophosphamide had contributed to the favourable outcomes. In conclusion, detection of serum KL-6 levels in ILDs associated with connective tissue diseases may be beneficial to making a definitive diagnosis, predicting the prognosis and monitoring the disease activity, which would be of great help in clinical practice. However, a well-designed clinical study with more patients and a longer follow-up period are required to arrive at a more conclusive judgment on the role of serum KL-6 in patients with ILDs.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>J F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China; Department of Nephrology and Rheumatology, The Third People's Hospital in Hubei Province, Wuhan 430000, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Y B</ForeName>
<Initials>YB</Initials>
<AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>An</LastName>
<ForeName>Y</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Z G</ForeName>
<Initials>ZG</Initials>
<AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Beijing Da Xue Xue Bao Yi Xue Ban</MedlineTA>
<NlmUniqueID>101125284</NlmUniqueID>
<ISSNLinking>1671-167X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C060192">MUC1 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018396">Mucin-1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D003240" MajorTopicYN="N">Connective Tissue Diseases</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003882" MajorTopicYN="Y">Dermatomyositis</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018396" MajorTopicYN="Y">Mucin-1</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012595" MajorTopicYN="N">Scleroderma, Systemic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>10</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>10</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>2</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29045979</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000144 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000144 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:29045979 |texte= [Changes of serum Krebs von den Lungen-6 levels in interstitial lung disease associated with dermatomyositis and secondary Sjögren's syndrome: a case report]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:29045979" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |